Pulse Biosciences, Inc.
General ticker "PLSE" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $1.1B (TTM average)
Pulse Biosciences, Inc. follows the US Stock Market performance with the rate: 40.9%.
Estimated limits based on current volatility of 2.7%: low 23.46$, high 24.78$
Factors to consider:
- Total employees count: 56 (-8.2%) as of 2023
- North America accounted for 0.0% of revenue in the fiscal year ended 2023-12-31
- Top business risk factors: Operational and conduct risks, Economic downturns and volatility, FDA actions/partner dependency, Key management loss, Technological obsolescence
- Current price 40.3% above estimated high
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.64$, 17.81$]
- 2026-12-31 to 2027-12-31 estimated range: [7.21$, 16.76$]
Financial Metrics affecting the PLSE estimates:
- Negative: with PPE of -14.5 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of -0.03 > -0.60
- Positive: Shareholder equity ratio, % of 85.32 > 64.29
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of 1.51 <= 5.46
- Negative: Industry earnings per price (median), % of 0 <= 0
Short-term PLSE quotes
Long-term PLSE plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.35MM |
| Operating Expenses | $43.57MM | $56.26MM | $77.29MM |
| Operating Income | $-43.57MM | $-56.26MM | $-76.94MM |
| Non-Operating Income | $1.36MM | $2.67MM | $4.16MM |
| R&D Expense | $27.80MM | $32.34MM | $44.72MM |
| Income(Loss) | $-42.21MM | $-53.59MM | $-72.78MM |
| Net Income(Loss)* | $-42.21MM | $-53.59MM | $-72.78MM |
| Stockholders Equity | $44.36MM | $114.86MM | $80.66MM |
| Inventory | $0.00MM | $0.00MM | $0.14MM |
| Assets | $59.15MM | $132.46MM | $94.54MM |
| Operating Cash Flow | $-33.04MM | $-36.34MM | $-54.12MM |
| Capital expenditure | $0.12MM | $0.12MM | $0.32MM |
| Investing Cash Flow | $-0.12MM | $-0.12MM | $-0.34MM |
| Financing Cash Flow | $16.39MM | $110.14MM | $17.15MM |
| Earnings Per Share** | $-0.88 | $-0.92 | $-1.08 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.